NCT00390650View on ClinicalTrials.gov

A North-American Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2007

Study Completion Date

November 30, 2007

Conditions
Anxiety
Interventions
DRUG

Saredutant

Trial Locations (2)

08807

Sanofi-Aventis, Bridgewater

Unknown

Sanofi-Aventis, Laval

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY